Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions View by Topic View by Date Must Reads In Prostate Cancer Prostate Cancer for March/April 2021 Consider potential cognitive complications prior to androgen deprivation therapy, Diabetes raises risk of prostate cancer mortality in obese men, Salivation inhibition fails to reduce radioiodine toxicity in prostate cancer, Highest positive surgical margin predicts poor survival after prostatectomy, Young minority men are underinformed about prostate cancer screening, More must reads Prostate Cancer for January/February 2021 Combined and monotherapy options yield similar oncological outcomes for hormone naïve metastatic prostate cancer, Treating bone loss with drug combination may boost outcomes in prostate cancer patients, Alcohol and genes connect to promote aggressive prostate cancer, Staufen1 RNA-binding protein drives prostate cancer development, Virtual microscopy holds its own for prostate cancer histopathology, More must readsProstate Cancer for November/December 2020 Antiandrogens linked to higher risk for fall, fracture in men with prostate cancer, Prostate cancer: Active surveillance not linked to higher mortality in Black men, Prostate cancer: Active surveillance is safe in the long term, Metastatic prostate cancer: EBRT improves survival in elderly patients with low PSA, Prostate cancer: Prolonged ADT reduces cardiorespiratory fitness, raises CV morality risk, More must readsProstate Cancer for September/October 2020 Nivolumab plus ipilimumab shows activity in mCRPC, CRPC: Comparison of apalutamide, enzalutamide, and darolutamide, ADT beneficial for prostate cancer patients with unfavorable intermediate risk, CRPC: Add-on darolutamide improves overall survival, Olaparib prolongs overall survival in metastatic castration-resistant prostate cancer, More must readsProstate Cancer for July/August 2020 Fracture risk in prostate cancer survivors, Radical prostatectomy vs deferred treatment for localized prostate cancer, mHSPC: Antibiotic prophylaxis for febrile neutropenia, Localized prostate cancer: HIFU may be an effective option, Prostate cancer: Ablation yields poor survival vs radiotherapy, More must readsPages1 2 3 last »
